

(301) 366-4960

(Issuer Telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

On June 26, 2015, Neuralstem, Inc. (the “Company”) announced that a poster entitled “Human Neural Stem Cells Expressing IGF-1: A Novel Cellular Therapy for Alzheimer’s Disease” was presented at the International Society for Stem Cell Research Annual Meeting in Stockholm, Sweden. A copy of the press release and poster are attached to this report as Exhibits 99.01 and 99.02, respectively.

Item 9.01 Financial Statement and Exhibits.

Exhibit No. Description

99.01	Press Release Dated June 26, 2015.
99.02	Poster presented at Meeting.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 26, 2015 Neuralstem, Inc.

/s/ Richard Garr
By: Richard Garr
Chief Executive Officer

INDEX OF EXHIBITS

Exhibit No. Description

99.01 Press Release Dated June 26, 2015.

99.02 Poster presented at Meeting.